Gonorrhea has been developing resistance to every antibiotic used to treat it since sulfa drugs were introduced in the 1930s. Each successive first-line treatment — penicillin, tetracycline, fluoroquinolones, azithromycin — has been rendered clinically unreliable by the extraordinary adaptability of Neisseria gonorrhoeae, a bacterium that has served as a textbook example of antibiotic resistance evolution for three generations of infectious disease specialists. In 2026, the story has moved from textbook warning to clinical emergency.
The World Health Organization's 2026 Global Antimicrobial Resistance and Use Surveillance System (GLASS) report documented a sixfold global rise in gonorrhea resistance to azithromycin — one of the two antibiotics that until recently formed the CDC's recommended dual-therapy regimen. The data compound a trend that has been building since 2019, when WHO surveillance first began documenting azithromycin resistance in gonorrhea strains from South and Southeast Asia. Those resistant strains have been traveling internationally, seeding themselves in sexual networks in North America and Europe.
In the United States, the CDC's Gonococcal Isolate Surveillance Project (GISP) — a sentinel surveillance network that tests gonorrhea isolates from STI clinics in major U.S. cities for antibiotic susceptibility — has documented the U.S. dimension of this trend with growing alarm. As of the most recent GISP data, azithromycin minimum inhibitory concentrations have risen steadily across gonorrhea isolates collected from sentinel sites nationwide. More ominously, a small but increasing number of ceftriaxone-resistant or ceftriaxone-reduced-susceptibility isolates have been identified in gonorrhea cases in multiple U.S. cities — representing the early signal of resistance to the last remaining reliably effective first-line treatment.
What This Means for the 1.6 Million Americans With Gonorrhea Each Year
Gonorrhea is the second most commonly reported bacterial STI in the United States, with approximately 1.6 million cases reported annually — though the CDC estimates the true burden may be two to three times higher due to underdiagnosis and underreporting. It affects the urethra, cervix, rectum, throat, and eyes, and untreated or undertreated infections can lead to pelvic inflammatory disease (PID), tubal scarring, ectopic pregnancy, and infertility in women, and epididymitis and infertility in men. Disseminated gonococcal infection (DGI) — when the bacteria spread to the blood, joints, and skin — can be life-threatening.
The practical management problem created by drug resistance is direct: if ceftriaxone fails — either because the patient was infected with a reduced-susceptibility strain that was not cleared, or because they were infected with a fully resistant strain — there are no remaining FDA-approved standard antibiotics with confirmed clinical efficacy for that situation. The last treatment option in this scenario is gentamicin — an injectable aminoglycoside antibiotic not typically used for STIs, with a more complex administration and monitoring profile — combined with azithromycin. This is what the 2026 CDC guidelines now address: updated treatment recommendations that specify precisely how to manage patients with gonorrhea treatment failures, suspected resistant strains, or documented ceftriaxone-reduced-susceptibility infections.
Prevention and What Patients Should Know
For individuals who are sexually active — particularly those with multiple partners or who have sex with someone who may have had other partners — regular gonorrhea screening (typically recommended annually for sexually active gay and bisexual men, and for sexually active women under 25) is the most important action. Consistent condom use provides strong but not absolute protection. Patients diagnosed with gonorrhea should inform recent sexual partners so they can also be tested and treated. Ensuring that follow-up "test of cure" testing is completed after treatment — particularly given the rising resistance landscape — is now more important than ever.
Frequently Asked Questions
Q: How serious is the drug-resistant gonorrhea problem in 2026?
A: WHO documented a sixfold global rise in azithromycin-resistant gonorrhea. Ceftriaxone-reduced-susceptibility and ceftriaxone-resistant strains are now documented in US cities. Ceftriaxone is the last broadly effective first-line treatment.
Q: Why has gonorrhea developed so much resistance?
A: Neisseria gonorrhoeae is exceptionally adept at acquiring and maintaining resistance mutations. Each first-line antibiotic introduced since the 1930s has eventually been rendered unreliable. High treatment volumes, incomplete treatment courses, and global spread of resistant strains all accelerate this process.
Q: What is the current CDC treatment recommendation?
A: Ceftriaxone 500 mg IM (or 1g for patients over 150 kg) in a single dose. Azithromycin is no longer recommended for routine co-administration due to widespread resistance. The 2026 guidelines specify protocols for treatment failures and suspected resistant cases.
Q: What should patients do if gonorrhea treatment does not work?
A: Return to a healthcare provider immediately. Request susceptibility testing on a new culture if possible. Discuss alternative regimens with your provider, who may consult with an infectious disease specialist or contact the CDC's STI treatment consultation service.
Q: Who should be routinely screened for gonorrhea?
A: Sexually active gay, bisexual, and other men who have sex with men (annually, and every 3–6 months for those with multiple partners); sexually active women under 25 (annually); pregnant women (at first prenatal visit); and anyone with new or multiple sexual partners.
